ID   IKKB_HUMAN              Reviewed;         756 AA.
AC   O14920; O75327;
DT   01-JUN-2001, integrated into UniProtKB/Swiss-Prot.
DT   01-JAN-1998, sequence version 1.
DT   02-NOV-2010, entry version 123.
DE   RecName: Full=Inhibitor of nuclear factor kappa-B kinase subunit beta;
DE            Short=I-kappa-B-kinase beta;
DE            Short=IKK-B;
DE            Short=IKK-beta;
DE            Short=IkBKB;
DE            EC=2.7.11.10;
DE   AltName: Full=I-kappa-B kinase 2;
DE            Short=IKK2;
DE   AltName: Full=Nuclear factor NF-kappa-B inhibitor kinase beta;
DE            Short=NFKBIKB;
GN   Name=IKBKB; Synonyms=IKKB;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND MUTAGENESIS OF LYS-44; SER-177 AND
RP   SER-181.
RC   TISSUE=Cervix carcinoma;
RX   MEDLINE=98008813; PubMed=9346484; DOI=10.1126/science.278.5339.860;
RA   Mercurio F., Zhu H., Murray B.W., Shevchenko A., Bennett B.L.,
RA   Li J.W., Young D.B., Barbosa M., Mann M., Manning A., Rao A.;
RT   "IKK-1 and IKK-2: cytokine-activated IkappaB kinases essential for NF-
RT   kappaB activation.";
RL   Science 278:860-866(1997).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND MUTAGENESIS OF LYS-44.
RX   MEDLINE=98008814; PubMed=9346485; DOI=10.1126/science.278.5339.866;
RA   Woronicz J.D., Gao X., Cao Z., Rothe M., Goeddel D.V.;
RT   "IkappaB kinase-beta: NF-kappaB activation and complex formation with
RT   IkappaB kinase-alpha and NIK.";
RL   Science 278:866-869(1997).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Heart;
RX   MEDLINE=99032998; PubMed=9813230; DOI=10.1016/S0378-1119(98)00462-4;
RA   Hu M.C.-T., Wang Y.-P.;
RT   "IkappaB kinase-alpha and -beta genes are coexpressed in adult and
RT   embryonic tissues but localized to different human chromosomes.";
RL   Gene 222:31-40(1998).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND GENE MAPPING.
RX   MEDLINE=98438415; PubMed=9763654;
RA   Shindo M., Nakano H., Sakon S., Yagita H., Mihara M., Okumura K.;
RT   "Assignment of IkappaB kinase beta (IKBKB) to human chromosome band
RT   8p12-->p11 by in situ hybridization.";
RL   Cytogenet. Cell Genet. 82:32-33(1998).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT TRP-554.
RG   SeattleSNPs variation discovery resource;
RL   Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 1-256.
RC   TISSUE=Lung;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   PROTEIN SEQUENCE OF 170-182, INACTIVATION BY YERSINIA YOPJ,
RP   ACETYLATION AT THR-180, AND MASS SPECTROMETRY.
RX   PubMed=17116858; DOI=10.1073/pnas.0608995103;
RA   Mittal R., Peak-Chew S.Y., McMahon H.T.;
RT   "Acetylation of MEK2 and I kappa B kinase (IKK) activation loop
RT   residues by YopJ inhibits signaling.";
RL   Proc. Natl. Acad. Sci. U.S.A. 103:18574-18579(2006).
RN   [8]
RP   IKK PHOSPHORYLATION.
RX   MEDLINE=99038238; PubMed=9819420;
RA   Nemoto S., DiDonato J.A., Lin A.;
RT   "Coordinate regulation of IkappaB kinases by mitogen-activated protein
RT   kinase kinase kinase 1 and NF-kappaB-inducing kinase.";
RL   Mol. Cell. Biol. 18:7336-7343(1998).
RN   [9]
RP   IDENTIFICATION IN A COMPLEX WITH CHUK; NFKBIA; RELA; IKBKAP AND
RP   MAP3K14.
RX   MEDLINE=98421679; PubMed=9751059; DOI=10.1038/26254;
RA   Cohen L., Henzel W.J., Baeuerle P.A.;
RT   "IKAP is a scaffold protein of the IkappaB kinase complex.";
RL   Nature 395:292-296(1998).
RN   [10]
RP   INTERACTION WITH SQSTM1; PRKCZ AND PRKCI.
RX   PubMed=10356400; DOI=10.1093/emboj/18.11.3044;
RA   Sanz L., Sanchez P., Lallena M.-J., Diaz-Meco M.T., Moscat J.;
RT   "The interaction of p62 with RIP links the atypical PKCs to NF-kappaB
RT   activation.";
RL   EMBO J. 18:3044-3053(1999).
RN   [11]
RP   PHOSPHORYLATION AT SER-177; SER-181; SER-670; SER-672; SER-675;
RP   SER-682; SER-689; SER-692; SER-695; SER-697; SER-705; SER-733; SER-740
RP   AND SER-750.
RX   MEDLINE=99212141; PubMed=10195894; DOI=10.1126/science.284.5412.309;
RA   Delhase M., Hayakawa M., Chen Y., Karin M.;
RT   "Positive and negative regulation of IkappaB kinase activity through
RT   IKKbeta subunit phosphorylation.";
RL   Science 284:309-313(1999).
RN   [12]
RP   REVIEW.
RX   MEDLINE=20178139; PubMed=10712233;
RA   Jobin C., Sartor R.B.;
RT   "The I kappa B/NF-kappa B system: a key determinant of mucosal
RT   inflammation and protection.";
RL   Am. J. Physiol. 278:C451-C462(2000).
RN   [13]
RP   INTERACTION WITH IKBKG AND TANK.
RX   PubMed=12133833; DOI=10.1074/jbc.M205069200;
RA   Chariot A., Leonardi A., Muller J., Bonif M., Brown K., Siebenlist U.;
RT   "Association of the adaptor TANK with the I kappa B kinase (IKK)
RT   regulator NEMO connects IKK complexes with IKK epsilon and TBK1
RT   kinases.";
RL   J. Biol. Chem. 277:37029-37036(2002).
RN   [14]
RP   IDENTIFICATION IN A COMPLEX WITH CREBBP; NCOA2; NCOA3; IKKA AND IKBKG.
RX   MEDLINE=21968797; PubMed=11971985;
RX   DOI=10.1128/MCB.22.10.3549-3561.2002;
RA   Wu R.-C., Qin J., Hashimoto Y., Wong J., Xu J., Tsai S.Y., Tsai M.-J.,
RA   O'Malley B.W.;
RT   "Regulation of SRC-3 (pCIP/ACTR/AIB-1/RAC-3/TRAM-1) coactivator
RT   activity by I kappa B kinase.";
RL   Mol. Cell. Biol. 22:3549-3561(2002).
RN   [15]
RP   COMPOSITION OF THE IKK COMPLEX.
RX   PubMed=12612076; DOI=10.1128/MCB.23.6.2029-2041.2003;
RA   Tegethoff S., Behlke J., Scheidereit C.;
RT   "Tetrameric oligomerization of IkappaB kinase gamma (IKKgamma) is
RT   obligatory for IKK complex activity and NF-kappaB activation.";
RL   Mol. Cell. Biol. 23:2029-2041(2003).
RN   [16]
RP   INTERACTION WITH TICAM1.
RX   PubMed=14739303; DOI=10.1074/jbc.M311629200;
RA   Han K.J., Su X., Xu L.-G., Bin L.H., Zhang J., Shu H.-B.;
RT   "Mechanisms of the TRIF-induced interferon-stimulated response element
RT   and NF-kappaB activation and apoptosis pathways.";
RL   J. Biol. Chem. 279:15652-15661(2004).
RN   [17]
RP   INTERACTION WITH NALP2.
RX   PubMed=15456791; DOI=10.1074/jbc.M406741200;
RA   Bruey J.-M., Bruey-Sedano N., Newman R., Chandler S., Stehlik C.,
RA   Reed J.C.;
RT   "PAN1/NALP2/PYPAF2, an inducible inflammatory mediator that regulates
RT   NF-kappaB and caspase-1 activation in macrophages.";
RL   J. Biol. Chem. 279:51897-51907(2004).
RN   [18]
RP   INTERACTION WITH ARRB1 AND ARRB2.
RX   PubMed=15173580; DOI=10.1073/pnas.0402851101;
RA   Witherow D.S., Garrison T.R., Miller W.E., Lefkowitz R.J.;
RT   "beta-Arrestin inhibits NF-kappaB activity by means of its interaction
RT   with the NF-kappaB inhibitor IkappaBalpha.";
RL   Proc. Natl. Acad. Sci. U.S.A. 101:8603-8607(2004).
RN   [19]
RP   S-NITROSYLATION AT CYS-179.
RX   PubMed=15184672; DOI=10.1073/pnas.0400588101;
RA   Reynaert N.L., Ckless K., Korn S.H., Vos N., Guala A.S., Wouters E.F.,
RA   van der Vliet A., Janssen-Heininger Y.M.;
RT   "Nitric oxide represses inhibitory kappaB kinase through S-
RT   nitrosylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 101:8945-8950(2004).
RN   [20]
RP   INTERACTION WITH NIBP.
RX   PubMed=15951441; DOI=10.1074/jbc.M501670200;
RA   Hu W.-H., Pendergast J.S., Mo X.-M., Brambilla R., Bracchi-Ricard V.,
RA   Li F., Walters W.M., Blits B., He L., Schaal S.M., Bethea J.R.;
RT   "NIBP, a novel NIK and IKK(beta)-binding protein that enhances NF-
RT   (kappa)B activation.";
RL   J. Biol. Chem. 280:29233-29241(2005).
RN   [21]
RP   UBIQUITINATION AT LYS-163.
RX   PubMed=16267042; DOI=10.1074/jbc.M508656200;
RA   Carter R.S., Pennington K.N., Arrate P., Oltz E.M., Ballard D.W.;
RT   "Site-specific monoubiquitination of IkappaB kinase IKKbeta regulates
RT   its phosphorylation and persistent activation.";
RL   J. Biol. Chem. 280:43272-43279(2005).
RN   [22]
RP   INTERACTION WITH MAVS.
RX   PubMed=16177806; DOI=10.1038/nature04193;
RA   Meylan E., Curran J., Hofmann K., Moradpour D., Binder M.,
RA   Bartenschlager R., Tschopp J.;
RT   "Cardif is an adaptor protein in the RIG-I antiviral pathway and is
RT   targeted by hepatitis C virus.";
RL   Nature 437:1167-1172(2005).
RN   [23]
RP   INTERACTION WITH YOPJ, AND ACETYLATION.
RX   PubMed=16728640; DOI=10.1126/science.1126867;
RA   Mukherjee S., Keitany G., Li Y., Wang Y., Ball H.L., Goldsmith E.J.,
RA   Orth K.;
RT   "Yersinia YopJ acetylates and inhibits kinase activation by blocking
RT   phosphorylation.";
RL   Science 312:1211-1214(2006).
RN   [24]
RP   INTERACTION WITH ATM.
RX   PubMed=16497931; DOI=10.1126/science.1121513;
RA   Wu Z.H., Shi Y., Tibbetts R.S., Miyamoto S.;
RT   "Molecular linkage between the kinase ATM and NF-kappaB signaling in
RT   response to genotoxic stimuli.";
RL   Science 311:1141-1146(2006).
RN   [25]
RP   IDENTIFICATION IN A MEMBRANE RAFT COMPLEX, AND SUBCELLULAR LOCATION.
RX   PubMed=17287217; DOI=10.1074/jbc.M609157200;
RA   Ohnuma K., Uchiyama M., Yamochi T., Nishibashi K., Hosono O.,
RA   Takahashi N., Kina S., Tanaka H., Lin X., Dang N.H., Morimoto C.;
RT   "Caveolin-1 triggers T-cell activation via CD26 in association with
RT   CARMA1.";
RL   J. Biol. Chem. 282:10117-10131(2007).
RN   [26]
RP   INTERACTION WITH FAF1.
RX   PubMed=17684021; DOI=10.1074/jbc.C700106200;
RA   Park M.Y., Moon J.H., Lee K.S., Choi H.I., Chung J., Hong H.J.,
RA   Kim E.;
RT   "FAF1 suppresses IkappaB kinase (IKK) activation by disrupting the IKK
RT   complex assembly.";
RL   J. Biol. Chem. 282:27572-27577(2007).
RN   [27]
RP   FUNCTION, AND INTERACTION WITH NLRC5.
RX   PubMed=20434986; DOI=10.1016/j.cell.2010.03.040;
RA   Cui J., Zhu L., Xia X., Wang H.Y., Legras X., Hong J., Ji J., Shen P.,
RA   Zheng S., Chen Z.J., Wang R.F.;
RT   "NLRC5 negatively regulates the NF-kappaB and type I interferon
RT   signaling pathways.";
RL   Cell 141:483-496(2010).
RN   [28]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-672, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [29]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-672, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [30]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RA   Colinge J., Superti-Furga G., Bennett K.L.;
RL   Submitted (OCT-2008) to UniProtKB.
RN   [31]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-672, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Embryonic kidney;
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [32]
RP   INTERACTION WITH TRIM21, MONOUBIQUITINATION, UBIQUITINATION
RP   INACTIVATION BY YERSINIA YOPJ, AND MUTAGENESIS OF LYS-163; SER-177 AND
RP   SER-181.
RX   PubMed=19675099; DOI=10.1093/jb/mvp127;
RA   Wada K., Niida M., Tanaka M., Kamitani T.;
RT   "Ro52-mediated monoubiquitination of IKK{beta} down-regulates
RT   NF-{kappa}B signalling.";
RL   J. Biochem. 146:821-832(2009).
RN   [33]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-670 AND SER-672, AND
RP   MASS SPECTROMETRY.
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [34]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-672, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [35]
RP   VARIANT [LARGE SCALE ANALYSIS] SER-360.
RX   PubMed=16959974; DOI=10.1126/science.1133427;
RA   Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D.,
RA   Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S.,
RA   Buckhaults P., Farrell C., Meeh P., Markowitz S.D., Willis J.,
RA   Dawson D., Willson J.K.V., Gazdar A.F., Hartigan J., Wu L., Liu C.,
RA   Parmigiani G., Park B.H., Bachman K.E., Papadopoulos N.,
RA   Vogelstein B., Kinzler K.W., Velculescu V.E.;
RT   "The consensus coding sequences of human breast and colorectal
RT   cancers.";
RL   Science 314:268-274(2006).
RN   [36]
RP   VARIANTS [LARGE SCALE ANALYSIS] SER-360; ARG-369; GLN-526; THR-710 AND
RP   LEU-734.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Acts as part of the IKK complex in the conventional
CC       pathway of NF-kappa-B activation and phosphorylates inhibitors of
CC       NF-kappa-B thus leading to the dissociation of the inhibitor/NF-
CC       kappa-B complex and ultimately the degradation of the inhibitor.
CC       Also phosphorylates NCOA3.
CC   -!- CATALYTIC ACTIVITY: ATP + [I-kappa-B protein] = ADP + [I-kappa-B
CC       phosphoprotein].
CC   -!- SUBUNIT: Component of the I-kappa-B-kinase (IKK) core complex
CC       consisting of CHUK, IKBKB and IKBKG; probably four alpha/CHUK-
CC       beta/IKBKB dimers are associated with four gamma/IKBKG subunits.
CC       The IKK core complex seems to associate with regulatory or adapter
CC       proteins to form a IKK-signalosome holo-complex. The IKK complex
CC       associates with TERF2IP/RAP1, leading to promote IKK-mediated
CC       phosphorylation of RELA/p65. Part of a complex composed of NCOA2,
CC       NCOA3, CHUK/IKKA, IKBKB, IKBKG and CREBBP. Part of a 70-90 kDa
CC       complex at least consisting of CHUK/IKKA, IKBKB, NFKBIA, RELA,
CC       IKBKAP and MAP3K14. Found in a membrane raft complex, at least
CC       composed of BCL10, CARD11, DPP4 and IKBKB. Interacts with SQSTM1
CC       through PRKCZ or PRKCI. Forms an NGF-induced complex with IKBKB,
CC       PRKCI and TRAF6. May interact with MAVS/IPS1. Interacts with
CC       NALP2. Interacts with TICAM1. Interacts with Yersinia yopJ.
CC       Interacts with FAF1; the interaction disrupts the IKK complex
CC       formation. Interacts with ATM. Part of a ternary complex
CC       consisting of TANK, IKBKB and IKBKG. Interacts with NIBP; the
CC       interaction is direct. Interacts with ARRB1 and ARRB2. Interacts
CC       with TRIM21. Interacts with NLRC5; prevents IKBKB phosphorylation
CC       and kinase activity.
CC   -!- INTERACTION:
CC       Self; NbExp=1; IntAct=EBI-81266, EBI-81266;
CC       O15111:CHUK; NbExp=3; IntAct=EBI-81266, EBI-81249;
CC       Q60680:Chuk (xeno); NbExp=2; IntAct=EBI-81266, EBI-646245;
CC       Q9Y6K9:IKBKG; NbExp=3; IntAct=EBI-81266, EBI-81279;
CC       Q13233:MAP3K1; NbExp=1; IntAct=EBI-81266, EBI-49776;
CC       Q99558:MAP3K14; NbExp=2; IntAct=EBI-81266, EBI-358011;
CC       Q7Z434:MAVS; NbExp=1; IntAct=EBI-81266, EBI-995373;
CC       Q9Y6Q9:NCOA3; NbExp=3; IntAct=EBI-81266, EBI-81196;
CC       P25963:NFKBIA; NbExp=3; IntAct=EBI-81266, EBI-307386;
CC       O09044:Snap23 (xeno); NbExp=1; IntAct=EBI-81266, EBI-1812522;
CC       Q9UGK3:STAP2; NbExp=3; IntAct=EBI-81266, EBI-1553984;
CC       Q92574:TSC1; NbExp=3; IntAct=EBI-81266, EBI-1047085;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm. Membrane raft. Note=Colocalized
CC       with DPP4 in membrane rafts.
CC   -!- TISSUE SPECIFICITY: Highly expressed in heart, placenta, skeletal
CC       muscle, kidney, pancreas, spleen, thymus, prostate, testis and
CC       peripheral blood.
CC   -!- PTM: Upon cytokine stimulation, phosphorylated on Ser-177 and Ser-
CC       181 by MEKK1 and/or MAP3K14/NIK; which enhances activity. Once
CC       activated, autophosphorylates on the C-terminal serine cluster;
CC       which decreases activity and prevents prolonged activation of the
CC       inflammatory response.
CC   -!- PTM: Acetylation of Thr-180 by Yersinia yopJ prevents
CC       phosphorylation and activation, thus blocking the I-kappa-B
CC       pathway.
CC   -!- PTM: Ubiquitinated. Monoubiquitination involves TRIM21 that leads
CC       to inhibition of Tax-induced NF-kappa-B signaling. According to
CC       PubMed:19675099, 'Ser-163' does not serve as a monoubiquitination
CC       site. According to PubMed:16267042, ubiquitination on 'Ser-163'
CC       modulates phosphorylation on C-terminal serine residues.
CC       Monoubiquitination by TRIM21 is dirupted by Yersinia yopJ.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Ser/Thr
CC       protein kinase family. I-kappa-B kinase subfamily.
CC   -!- SIMILARITY: Contains 1 protein kinase domain.
CC   -!- WEB RESOURCE: Name=SeattleSNPs;
CC       URL="http://pga.gs.washington.edu/data/ikbkb/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF029684; AAC51860.1; -; mRNA.
DR   EMBL; AF080158; AAD08997.1; -; mRNA.
DR   EMBL; AF031416; AAC64675.1; -; mRNA.
DR   EMBL; AY663108; AAT65965.1; -; Genomic_DNA.
DR   EMBL; BC006231; AAH06231.1; -; mRNA.
DR   IPI; IPI00024709; -.
DR   RefSeq; NP_001177649.1; -.
DR   RefSeq; NP_001547.1; -.
DR   UniGene; Hs.597664; -.
DR   PDB; 3BRT; X-ray; 2.25 A; A/C=701-742.
DR   PDB; 3BRV; X-ray; 2.20 A; A/C=701-745.
DR   PDBsum; 3BRT; -.
DR   PDBsum; 3BRV; -.
DR   ProteinModelPortal; O14920; -.
DR   SMR; O14920; 15-288.
DR   DIP; DIP-27527N; -.
DR   IntAct; O14920; 83.
DR   MINT; MINT-107608; -.
DR   STRING; O14920; -.
DR   PhosphoSite; O14920; -.
DR   PRIDE; O14920; -.
DR   Ensembl; ENST00000342222; ENSP00000339151; ENSG00000104365.
DR   GeneID; 3551; -.
DR   UCSC; uc003xow.1; human.
DR   CTD; 3551; -.
DR   GeneCards; GC08P042146; -.
DR   H-InvDB; HIX0007480; -.
DR   HGNC; HGNC:5960; IKBKB.
DR   HPA; CAB004447; -.
DR   HPA; HPA001249; -.
DR   MIM; 603258; gene.
DR   PharmGKB; PA29776; -.
DR   HOGENOM; HBG358635; -.
DR   HOVERGEN; HBG018241; -.
DR   InParanoid; O14920; -.
DR   OMA; PGQLMSQ; -.
DR   PhylomeDB; O14920; -.
DR   BRENDA; 2.7.11.10; 247.
DR   Pathway_Interaction_DB; nfkappabatypicalpathway; Atypical NF-kappaB pathway.
DR   Pathway_Interaction_DB; bcr_5pathway; BCR signaling pathway.
DR   Pathway_Interaction_DB; nfkappabcanonicalpathway; Canonical NF-kappaB pathway.
DR   Pathway_Interaction_DB; fcer1pathway; Fc-epsilon receptor I signaling in mast cells.
DR   Pathway_Interaction_DB; foxopathway; FoxO family signaling.
DR   Pathway_Interaction_DB; il1pathway; IL1-mediated signaling events.
DR   Pathway_Interaction_DB; p75ntrpathway; p75(NTR)-mediated signaling.
DR   Pathway_Interaction_DB; tcrpathway; TCR signaling in naive CD4+ T cells.
DR   Pathway_Interaction_DB; cd8tcrpathway; TCR signaling in naive CD8+ T cells.
DR   Pathway_Interaction_DB; tnfpathway; TNF receptor signaling pathway.
DR   Pathway_Interaction_DB; trail_pathway; TRAIL signaling pathway.
DR   Reactome; REACT_11061; Signalling by NGF.
DR   Reactome; REACT_6900; Signaling in Immune system.
DR   DrugBank; DB01169; Arsenic trioxide.
DR   DrugBank; DB00995; Auranofin.
DR   NextBio; 13864; -.
DR   ArrayExpress; O14920; -.
DR   Bgee; O14920; -.
DR   CleanEx; HS_IKBKB; -.
DR   Genevestigator; O14920; -.
DR   GermOnline; ENSG00000104365; Homo sapiens.
DR   GO; GO:0045121; C:membrane raft; IEA:UniProtKB-SubCell.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0008384; F:IkappaB kinase activity; IEA:EC.
DR   GO; GO:0016563; F:transcription activator activity; NAS:UniProtKB.
DR   GO; GO:0006916; P:anti-apoptosis; EXP:Reactome.
DR   GO; GO:0051092; P:positive regulation of NF-kappaB transcript...; IDA:MGI.
DR   InterPro; IPR022007; IKKbetaNEMObind.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000719; Prot_kinase_cat_dom.
DR   InterPro; IPR017442; Se/Thr_prot_kinase-like_dom.
DR   InterPro; IPR008271; Ser/Thr_prot_kinase_AS.
DR   InterPro; IPR019955; Ubiquitin_supergroup.
DR   Pfam; PF12179; IKKbetaNEMObind; 1.
DR   Pfam; PF00069; Pkinase; 1.
DR   SUPFAM; SSF56112; Kinase_like; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; FALSE_NEG.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; ATP-binding; Complete proteome; Cytoplasm;
KW   Direct protein sequencing; Isopeptide bond; Kinase; Membrane;
KW   Nucleotide-binding; Phosphoprotein; Polymorphism; S-nitrosylation;
KW   Serine/threonine-protein kinase; Transferase; Ubl conjugation.
FT   CHAIN         1    756       Inhibitor of nuclear factor kappa-B
FT                                kinase subunit beta.
FT                                /FTId=PRO_0000086013.
FT   DOMAIN       15    300       Protein kinase.
FT   DOMAIN      458    479       Leucine-zipper.
FT   NP_BIND      21     29       ATP (By similarity).
FT   REGION      737    742       NEMO-binding.
FT   ACT_SITE    145    145       Proton acceptor (By similarity).
FT   BINDING      44     44       ATP (By similarity).
FT   MOD_RES      23     23       Phosphothreonine (By similarity).
FT   MOD_RES     177    177       Phosphoserine.
FT   MOD_RES     179    179       S-nitrosocysteine.
FT   MOD_RES     180    180       O-acetylthreonine; by Yersinia yopJ.
FT   MOD_RES     181    181       Phosphoserine.
FT   MOD_RES     670    670       Phosphoserine; by autocatalysis
FT                                (Probable).
FT   MOD_RES     672    672       Phosphoserine; by autocatalysis
FT                                (Probable).
FT   MOD_RES     675    675       Phosphoserine; by autocatalysis
FT                                (Probable).
FT   MOD_RES     682    682       Phosphoserine; by autocatalysis
FT                                (Probable).
FT   MOD_RES     689    689       Phosphoserine; by autocatalysis
FT                                (Probable).
FT   MOD_RES     692    692       Phosphoserine; by autocatalysis
FT                                (Probable).
FT   MOD_RES     695    695       Phosphoserine; by autocatalysis
FT                                (Probable).
FT   MOD_RES     697    697       Phosphoserine; by autocatalysis
FT                                (Probable).
FT   MOD_RES     705    705       Phosphoserine; by autocatalysis
FT                                (Probable).
FT   MOD_RES     733    733       Phosphoserine; by autocatalysis
FT                                (Probable).
FT   MOD_RES     740    740       Phosphoserine; by autocatalysis
FT                                (Probable).
FT   MOD_RES     750    750       Phosphoserine; by autocatalysis
FT                                (Probable).
FT   CROSSLNK    163    163       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in ubiquitin).
FT   VARIANT     360    360       A -> S (in breast cancer samples;
FT                                infiltrating ductal carcinoma; somatic
FT                                mutation).
FT                                /FTId=VAR_035626.
FT   VARIANT     369    369       Q -> R (in dbSNP:rs56411242).
FT                                /FTId=VAR_040567.
FT   VARIANT     526    526       R -> Q (in dbSNP:rs2272736).
FT                                /FTId=VAR_040568.
FT   VARIANT     554    554       R -> W (in dbSNP:rs17875749).
FT                                /FTId=VAR_021124.
FT   VARIANT     710    710       A -> T (in dbSNP:rs34309584).
FT                                /FTId=VAR_040569.
FT   VARIANT     734    734       F -> L (in dbSNP:rs56301637).
FT                                /FTId=VAR_040570.
FT   VARIANT     736    736       A -> T (in dbSNP:rs17611716).
FT                                /FTId=VAR_051628.
FT   MUTAGEN      44     44       K->A: Loss of kinase activity and no
FT                                effect on binding to NIK.
FT   MUTAGEN     163    163       K->R: Monoubiquitinated; when associated
FT                                with E-177 and E-181.
FT   MUTAGEN     177    177       S->A: Decrease of activity.
FT   MUTAGEN     177    177       S->E: Full activation. Interaction with
FT                                TRIM21 is enhanced; when associated with
FT                                E-181. Monoubiquitinated; when associated
FT                                with R-163 and E-181. Strongly promoted
FT                                NF-kappa-B gene expression; when
FT                                associated with E-181.
FT   MUTAGEN     181    181       S->A: Decrease of activity.
FT   MUTAGEN     181    181       S->E: Full activation. Interaction with
FT                                TRIM21 is enhanced; when associated with
FT                                E-177. Monoubiquitinated; when associated
FT                                with R-163 and E-177. Strongly promoted
FT                                NF-kappa-B gene expression; when
FT                                associated with E-177.
FT   CONFLICT    231    255       WHSKVRQKSEVDIVVSEDLNGTVKF -> CVRMWPGTVAHS
FT                                CNPSTLGGRGRWI (in Ref. 6; AAH06231).
FT   HELIX       707    729
FT   HELIX       734    736
FT   HELIX       740    742
SQ   SEQUENCE   756 AA;  86564 MW;  F9CADF671AE9E14E CRC64;
     MSWSPSLTTQ TCGAWEMKER LGTGGFGNVI RWHNQETGEQ IAIKQCRQEL SPRNRERWCL
     EIQIMRRLTH PNVVAARDVP EGMQNLAPND LPLLAMEYCQ GGDLRKYLNQ FENCCGLREG
     AILTLLSDIA SALRYLHENR IIHRDLKPEN IVLQQGEQRL IHKIIDLGYA KELDQGSLCT
     SFVGTLQYLA PELLEQQKYT VTVDYWSFGT LAFECITGFR PFLPNWQPVQ WHSKVRQKSE
     VDIVVSEDLN GTVKFSSSLP YPNNLNSVLA ERLEKWLQLM LMWHPRQRGT DPTYGPNGCF
     KALDDILNLK LVHILNMVTG TIHTYPVTED ESLQSLKARI QQDTGIPEED QELLQEAGLA
     LIPDKPATQC ISDGKLNEGH TLDMDLVFLF DNSKITYETQ ISPRPQPESV SCILQEPKRN
     LAFFQLRKVW GQVWHSIQTL KEDCNRLQQG QRAAMMNLLR NNSCLSKMKN SMASMSQQLK
     AKLDFFKTSI QIDLEKYSEQ TEFGITSDKL LLAWREMEQA VELCGRENEV KLLVERMMAL
     QTDIVDLQRS PMGRKQGGTL DDLEEQAREL YRRLREKPRD QRTEGDSQEM VRLLLQAIQS
     FEKKVRVIYT QLSKTVVCKQ KALELLPKVE EVVSLMNEDE KTVVRLQEKR QKELWNLLKI
     ACSKVRGPVS GSPDSMNASR LSQPGQLMSQ PSTASNSLPE PAKKSEELVA EAHNLCTLLE
     NAIQDTVREQ DQSFTALDWS WLQTEEEEHS CLEQAS
//
